DELFI Diagnostics

DELFI Diagnostics (operating at delfidiagnostics.com) is a pioneering biotechnology company specializing in early cancer detection through liquid biopsy technology. Founded as an American innovator, DELFI leverages AI, machine learning, and whole-genome sequencing to analyze DNA fragmentation patterns in blood—uncovering subtle signals that traditional methods miss. Unlike invasive procedures like biopsies, DELFI’s blood-based tests aim to identify cancer at its earliest, most treatable stages, particularly for high-risk patients. Under the hood, the platform deciphers genome-wide fragmentation profiles, a novel approach that transforms liquid blood samples into actionable diagnostic insights. This empowers clinicians to detect diseases like lung cancer with unprecedented sensitivity, enabling proactive interventions before symptoms manifest. Backed by a $225 million Series B financing round, DELFI is accelerating the development of a globally accessible portfolio of tests to redefine cancer screening.